Hepatitis B is a life threatening liver
infection caused by hepatitis B virus. Adults who get affected by
hepatitis B virus for a short time and then get cured is known as acute
hepatitis B. Infection that lasts for a long time is known as chronic
hepatitis B. Vaccine is the most preferred choice of doctors and
physicians to protect people from the disease. The vaccine prevents the
infection and stops development of liver cancer and chronic disease
caused by hepatitis B. It can cause a long term infection and put people
at high risk of liver cancer and cirrhosis that may lead to death.
Globally, hepatitis B is one of the major health problems that spreads
by mucosal or percutaneous exposure as well as through menstrual,
seminal, saliva, and vaginal fluids. Hepatitis B can occur due to sexual
transmission, by having contact with sex workers and sex with multiple
partners. Transmission of disease may also occur due to reuse of
syringes and needles both among persons who inject drugs and in health
care settings. Moreover, it may occur during surgical, medical, and
dental procedures, and use of razors that are contaminated with infected
blood. Infants and young children mostly get chronic hepatitis B.
Report Overview @ https://www.transparencymarketresearch.com/hepatitis-b-market.html
Hepatitis B Therapeutics Market: Dynamics
Limited access to treatment and diagnosis
of hepatitis B in many resource constrained settings and increasing
prevalence of hepatitis B infections are likely to drive the global
hepatitis B therapeutics market during the forecast period. Rising
awareness and increasing affordability are some of the key factors that
will increase the rate of diagnosis before a person having advanced
liver disease. According to the World Health Organization (WHO),
infection of chronic hepatitis B is most common in infants. Rising
incidence of hepatitis B infections is a major driver of the market.
Less availability of antibiotics in the market and effectiveness of
antivirals against hepatitis B infections is likely to propel the market
during the forecast period. Prevalence of hepatitis B is increasing
steadily across the globe. Medications and treatment options are highly
expensive. These are the major drivers of the hepatitis B therapeutics
market.
Hepatitis B Therapeutics Market: Region-wise Outlook
In terms of region, the hepatitis B
therapeutics market has been segmented into North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa. North
America dominated the hepatitis B therapeutics market owing to the high
awareness levels, availability of improved infrastructure, and favorable
government initiatives relating to the promotion of hepatitis B
therapeutics. Europe is the second largest market for hepatitis B
therapeutics driven by rising geriatric population, high rates of
chronic infections in Central and Eastern Europe. Prevalence of
hepatitis B is the highest in Middle East & Africa where adult
population is chronically infected. According to the WHO, it is
estimated that 2% to 5% of general population is affected chronically in
Asia Pacific. Most people with liver cancer die within diagnosis as
there are limited treatment options.
Hepatitis B Therapeutics Market: Key Players
Major players operating in the global
hepatitis B therapeutics market are GlaxoSmithKline plc, Bristol-Myers
Squibb, Novira Therapeutics, Johnson & Johnson, Abivax SA, F.
Hoffmann- La Roche, Novartis AG, and Merck & Co. The increasing
competition among key players is likely to drive the global hepatitis B
therapeutics market during the forecast period.
No comments:
Post a Comment